Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022

Kao-Ping Chua; Thuy D Nguyen; Jason Zhang; Rena M Conti; Pooja Lagisetty; Amy S Bohnert

doi:10.1001/jama.2023.1207

Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022

JAMA. 2023 Apr 25;329(16):1402-1404. doi: 10.1001/jama.2023.1207.

Authors

Kao-Ping Chua¹, Thuy D Nguyen², Jason Zhang¹, Rena M Conti³, Pooja Lagisetty⁴, Amy S Bohnert⁵

Affiliations

¹ Susan B. Meister Child Health and Evaluation Research Center, University of Michigan Medical School, Ann Arbor.
² Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor.
³ Department of Markets, Public Policy, and Law, Boston University Questrom School of Business, Boston, Massachusetts.
⁴ Department of Medicine, University of Michigan Medical School, Ann Arbor.
⁵ Department of Anesthesiology, University of Michigan Medical School, Ann Arbor.

No abstract available

Plain language summary

This study uses data from an all-payer database of prescriptions dispensed in US retail pharmacies to assess trends in buprenorphine initiation and retention during 2016-2022.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Analgesics, Opioid / therapeutic use
Buprenorphine* / therapeutic use
Drug Prescriptions / statistics & numerical data
Humans
Medication Adherence* / statistics & numerical data
Naloxone / therapeutic use
Opioid-Related Disorders* / drug therapy
Patient Compliance / statistics & numerical data
Pharmacies / statistics & numerical data
United States / epidemiology

Substances

Analgesics, Opioid
Buprenorphine
Naloxone

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding